anti-BCMA CAR T-cell therapy (Casebia Therapeutics)

N/A

Report date: 2025/01/26 16:13:46

Base Information

Drug Nameanti-BCMA CAR T-cell therapy (Casebia Therapeutics)

Drug Alias NameTRAC targeted anti-BCMA CAR-T cells (Casebia Therapeutics)

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionTumor necrosis factor ligand superfamily member 13 modulators

TargetsTumor necrosis factor ligand superfamily member 13

Therapy Area/IndicationsAutoimmune Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCasebia Therapeutics Llc

China Registration ClassN/A

Develop Information

Active CompaniesCasebia Therapeutics Llc

Inactive CompaniesN/A

Active IndicationsAutoimmune Diseases

Inactive IndicationsN/A

Other Information

ATC CodeN/A